Mostrando 10 resultados de: 10
Filtros aplicados
Publisher
Cancer Biology and Therapy(2)
Cancers(1)
Current Cancer Drug Targets(1)
Frontiers in Oncology(1)
Frontiers in Pharmacology(1)
Área temáticas
Enfermedades(10)
Farmacología y terapéutica(5)
Medicina y salud(4)
Ginecología, obstetricia, pediatría, geriatría(1)
Microorganismos, hongos y algas(1)
Origen
scopus(10)
Chronic vaccination with a therapeutic egf-based cancer vaccine: A review of patients receiving long lasting treatment
ArticleAbstract: Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despiPalabras claves:Cancer Vaccines, chronic vaccination, EGF, eGFRAutores:González G., Lage Davila A., Tania CrombetFuentes:scopusBivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
ArticleAbstract: Nimotuzumab is an EGFR-targeting antibody that has demonstrated encouraging clinical results in thePalabras claves:Affinity, Avidity, Cancer immunotherapy, eGFR, monoclonal antibodies, nimotuzumab, Tumor targetingAutores:Fernandez L.E., Garrido G., Gracia E., Iznaga N., Kerbel R.S., Pérez R., Rabasa A., Tania Crombet, Tikhomirov I.A., Yang E.Fuentes:scopusA pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopusA view on EGFR-targeted therapies from the oncogene-addiction perspective
ArticleAbstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenonPalabras claves:CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapyAutores:de Leon J., Moreno E., Pérez R., Tania CrombetFuentes:scopusEGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects
ReviewAbstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guiPalabras claves:biological therapy, Cancer treatment, eGFR, nimotuzumab, Targeted therapyAutores:Garrido G., Moreno E., Pérez R., Tania CrombetFuentes:scopusNimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
ArticleAbstract: EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis.Palabras claves:brief research report nimotuzumab, covid-19, eGFR, FIBROSIS, inflammation, Monoclonal antibody, SARS-COV-2Autores:Batista D., Cabrera L., Diaz H., Domeq M., Gorte A., Hernández A., Hernández R., Jiménez J., Jova J.H., Luaces P.L.o., Martínez A., Medel L., Pérez Ruiz L., Porto L., Ramos M., Saavedra Hernández D., Sánchez L., Tania Crombet, Travieso N., Troche M., Valdés L., Valls A.R.Fuentes:scopusNimotuzumab for Patients With Inoperable Cancer of the Head and Neck
ReviewAbstract: EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasisPalabras claves:eGFR, head and neck, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Iznaga-Escobar N., Mazorra Z., Mestre Fernández B., Tania CrombetFuentes:scopusNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
ReviewAbstract: Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptorPalabras claves:eGFR, glioma, Humanized, Monoclonal antibody, nimotuzumab, Overall survival, SCCHNAutores:Arvind A., Eswaraiah A., Iyer H., Piedra-Sierra P., Ramakrishnan M., Saurez G., Tania CrombetFuentes:scopusNimotuzumab: beyond the EGFR signaling cascade inhibition
ReviewAbstract: One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activatesPalabras claves:antibody-dependent cell mediated cytotoxicity (ADCC), eGFR, HLA class I molecules, monoclonal antibodies, Natural killer cells, T cellsAutores:Chao L., Iznaga N., Lavastida A., Mazorra Z., Ramos M., Sanchez B., Tania CrombetFuentes:scopusImmune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
ArticleAbstract: SARS-CoV-2 infection causes a range of clinical presentations and induces changes in both innate andPalabras claves:covid-19, eGFR, inflammation, nimotuzumab, SARS-COV-2, T cellsAutores:Añe-Kouri A.L., Armada J.J., González Y.Z., Gregorich E.M.L., Londres H.D., Luaces P.L.o., Martínez A.H., Medel L., Mena J., Ramos M., Saavedra Hernández D., Sánchez Y.H., Tania Crombet, Troche M.Fuentes:scopus